FUNDAMENTALS:
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
註釋
Target: 165
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。